Navigation Links
Debio in Medical News

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 Debiopharm Releases Phase Ib Results of debio 025 II-59 Nabi Biopharmaceuticals Starts Proof-Of-Concept Trial for Civacir II-60 Peregrine Announces Positive Results for Bavituximab II-60 ...

Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

...not only with different regulatory agencies, but also different partners. Furthermore, our FDA inspected research development and production facility, debio R.P., will produce both products for global distribution." The NDA for the 6 month formulation of Trelstar(R) is supported by data from a phase III ...
Debio in Medical Technology

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

LAUSANNE, Switzerland and WOBURN, Massachusetts, August 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Mercury Therapeutics, Inc. (Mercury), a ...

Clinical Update - Debio 025 in Hepatitis C

LAUSANNE, Switzerland, April 28 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, presented results from a phase IIa study with Debio 025, a selective cyclophilin (...

Clinical Update - Debio 025 in Hepatitis C

LAUSANNE, Switzerland, January 26 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today the randomisation of its first patient in a phase IIb clinical study with Deb...

Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND

LAUSANNE, Switzerland, October 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today that the first healthy elderly subjects have been randomised in a clinical bi...

Clinical Update - Debio 025 in Hepatitis C

Presentation of Phase IIa Efficacy Results LAUSANNE, Switzerland, April 28 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions, particularly oncology, presented positive efficacy resu...

Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure

LAUSANNE, Switzerland, and POMEZIA, Italy, April 2 /PRNewswire/ -- - Presentation of Phase IIa Efficacy Results Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions, particularly oncology and cardiology, and sig...

Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV

A Unique Viral Kinetics Profile LAUSANNE, Switzerland, April 19, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented additional results of a previous phase Ib, 15 day study with cycl...

Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease

Presentation of Final Phase I Monthly Implant and Phase IIa Daily Oral Results LAUSANNE, Switzerland, June 11, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented final results of tw...

Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding

...iate, filed its Complete Response to the approvable letter received from the United States (U.S.) Food and Drug Administration (FDA) for Sanvar(R), or debio 8609 (vapreotide acetate). The immediate release formulation of Sanvar(R), a somatostatin analogue, is used in the treatment of acute esophageal varic...

Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment

...rfere with pathways controlling cell fate specification. The project, named debio 0826, could lead to the development of potential therapeutic compounds and ...ector of the Biomolecular Screening Facility (BSF), two groups at the EPFL. debio 0826 will benefit from the multiple molecular and genetic tools generated b...
Debio in Biological Technology

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and MSM Protein Technologies (MSM), a human ...

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Fl...

Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions

LAUSANNE, Switzerland and PARIS, February 9 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Pharmaleads SAS, a science driven drug discovery and early development company,...

Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

LAUSANNE, Switzerland and BANGALORE, India, November 20 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based fully...

Clinical Update - Debio 9902 SR in Alzheimer's Disease

Successful DSMB Review From Ongoing Phase II BRAINz Study LAUSANNE, Switzerland, March 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced today that fo...
Other Tags
(Date:4/24/2014)... substantial proportion of risk for developing autism spectrum disorders ... interconnected biological pathways, according to researchers from the Icahn ... broad study of almost 2,500 families in the United ... "Convergence of Genes and Cellular Pathways Dysregulated in Autism ... American Journal of Human Genetics on April 24. ...
(Date:4/24/2014)... Scientific research at UT Southwestern Medical Center previously ... completely, whereas the adult heart lacks this ability. New ... the heart loses its incredible regenerative capability in adulthood, ... , Yes, oxygen. It is well-known that a major ... throughout the body. But at the same time, oxygen ...
(Date:4/24/2014)... Changes in managing patients before, during and after colorectal ... readmission rates, according to researchers who led a study ... practice, called enhanced recovery, is easier on patients before ... evacuation that are typically prescribed. After surgery, patients are ... possible, leading to faster recoveries. , Among findings published ...
(Date:4/24/2014)... terminology, and the relevance of palliation in advanced ... randomized controlled trials (RCTs). This is the result ... Quality and Efficiency in Health Care (IQWiG), which ... Together with external experts, IQWiG analysed studies on ... malignant melanoma, and pancreatic cancer. For this purpose, ...
(Date:4/24/2014)... A Finnish team of researchers was the first in ... which is a tumour of the jaw. , Ameloblastoma ... recur after treatment. Ameloblastoma is most often found in ... by surgery, often resulting in tissue deficiencies in the ... suitable drug therapy could reduce the need for surgery ...
Breaking Medicine News(10 mins):Health News:Genetic alterations in shared biological pathways as major risk factor for ASD 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3
(Date:4/24/2014)... turtle is the largest river turtle in North America, ... almost a century. Now researchers from Florida and the ... one species but three. , Examining museum specimens ... in this ancient reptile. , Once heavily hunted for ... of Campbell,s Turtle Soup in the 1960s the ...
(Date:4/24/2014)... RICHLAND, Wash. A common plant puts out a welcome ... the mat,s molecular mix. , The study published this week ... reveals new targets during the battle between microbe and ... team showed that the humble and oft-studied plant Arabidopsis ... from a pathogen. It,s as if a hostile army were ...
(Date:4/23/2014)... "playwright" to their resumes in an effort to aid ... ethical issues as genomic science transitions to bedside healthcare, ... , Until now the plays of Karen H. ... and by, their peers and others in the genomics ... With Oxford University Press, publication of the book ...
Breaking Biology News(10 mins):Two new US turtle species described 2Two new US turtle species described 3How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3
Other Contents